Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis

Published:2023-10 Issue: Volume:64 Page:102181
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Caruso Irene^ORCID,Di Gioia Ludovico,Di Molfetta Sergio,Cignarelli Angelo,Palmer Suetonia Cressida,Natale Patrizia,Strippoli Giovanni F.M.,Perrini Sebastio,Natalicchio Annalisa,Laviola Luigi,Giorgino Francesco^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference49 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition;Saeedi;Diabetes Res Clin Pract,2019

2. Trends in diabetes treatment and control in U.S. Adults, 1999-2018;Fang;N Engl J Med,2021

3. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art;Nauck;Mol Metab,2021

4. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action;Ussher;Nat Rev Cardiol,2023

5. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes;De Block;Diabetes Obes Metab,2022

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide for the management of diabesity: The real-world experience;World Journal of Methodology;2024-09-20

2. Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care;Diabetologia;2024-08-23

3. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database;Journal of Endocrinological Investigation;2024-08-14

4. Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials;Metabolism Open;2024-06

5. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison;Diabetes Research and Clinical Practice;2024-06